<SEC-DOCUMENT>0000886163-14-000085.txt : 20140717
<SEC-HEADER>0000886163-14-000085.hdr.sgml : 20140717
<ACCEPTANCE-DATETIME>20140717080613
ACCESSION NUMBER:		0000886163-14-000085
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140717
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140717
DATE AS OF CHANGE:		20140717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		14979293

	BUSINESS ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ligandform8-k_preliminaryf.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>LigandForm8-K_PreliminaryFinancialResultsandShareRepurchase </title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sD57512C3978BB3C65084420FC019372A"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;font-weight:bold;">______________</font></div><div style="line-height:120%;padding-top:21px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">FORM 8&#8209;K</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;font-weight:bold;">______________</font></div><div style="line-height:120%;padding-top:21px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Report (Date of earliest event reported): July 17, 2014</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:8pt;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;padding-top:21px;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;font-weight:bold;">______________</font></div><div style="line-height:120%;padding-top:21px;text-align:left;text-indent:108px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">77-0160744</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11119 North Torrey Pines Road, Suite 200</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">La Jolla, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">92037</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Zip Code)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(858)&#160;550-7500</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425) </font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sD57512C3978BB3C65084420FC019372A"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sD57512C3978BB3C65084420FC019372A"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2.02 Results of Operations and Financial Condition.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 17, 2014, Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221; or &#8220;Ligand&#8221;) issued a press release announcing expected revenue for the quarter ended June 30, 2014. A copy of this press release is furnished herewith as Exhibit 99.1.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including the press release attached hereto as Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;8.01 Other Events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 17, 2014, the Company issued a press release announcing that its Board of Directors has authorized the Company to repurchase up to $10.0 million of its common stock from time to time in open-market transactions over the next 12 months.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="9%"></td><td width="91%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;9.01</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="4%"></td><td width="96%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibits.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="11%"></td><td width="6%"></td><td width="83%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:6px;padding-bottom:6px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:6px;padding-bottom:6px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release of the Company dated July 17, 2014.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sD57512C3978BB3C65084420FC019372A"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;padding-left:144px;text-indent:-96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:26px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has caused this report to be signed on its behalf by the undersigned.</font></div><div style="line-height:120%;padding-bottom:48px;text-align:left;padding-left:240px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="line-height:120%;padding-left:25px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="42%"></td><td width="58%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: July 17, 2014</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:   </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Nishan de Silva</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;<br>Name:   Nishan de Silva <br>Title:   Vice President, Finance and Strategy and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.01709401709401%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="23%"></td><td width="2%"></td><td width="75%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sD57512C3978BB3C65084420FC019372A"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="19%"></td><td width="2%"></td><td width="79%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:6px;padding-bottom:6px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:6px;padding-bottom:6px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release of the Company dated July 17, 2014.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ligandpre-announcessecondq.htm
<DESCRIPTION>EXHIBIT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>LigandPre-AnnouncesSecondQuarterResults </title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s6A726213AB2B5F51C0EF420EF0C87306"></a><div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:100%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;"><img src="ligandlogo06.jpg" style="height:70px;width:196px;"></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Contacts:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:467px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="238px"></td><td width="228px"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contacts:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand Pharmaceuticals Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LHA</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John L. Higgins, President and CEO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bruce Voss, bvoss@lhai.com</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(858) 550-7500</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(310) 691-7100</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Ligand Reports Second Quarter Revenues and Announces Share Repurchase Program</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Sets date for second quarter conference call</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SAN DIEGO (July 17, 2014) - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)</font><font style="font-family:inherit;font-size:10pt;">&#32;today reported that total revenues for the second quarter of 2014 are expected to be approximately $10.6 million. This exceeds guidance Ligand issued on May 7, 2014 for total revenues to be $9.0 million to $9.5 million.  The incremental increase in revenue over previous guidance will result in additional earnings and cash-flow for the second quarter.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Separately, the Company&#8217;s Board of Directors has authorized a share repurchase program of up to $10 million over the next 12 months.&#160; With this authorization, the Company may repurchase common stock from time to time in open-market transactions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;We are pleased with the financial performance of all aspects of our business and to be reporting second quarter revenues that are meaningfully above our previous guidance,&#8221; said Nishan de Silva, Chief Financial Officer of Ligand Pharmaceuticals, Inc.&#160; &#8220;Our diverse range of revenues is setting the foundation for continued growth in profits and cash flow from operations.&#160; We closed the second quarter with the highest cash balance we have had in more than two years while paying down debt during that period, and now will be debt free at the end of this month.&#160; We are pleased to be in a position to put some of our cash to work under this newly authorized share repurchase program.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Second Quarter Earnings Call</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;Monday, August 4, 2014.  6:00 a.m. Pacific time (9:00 a.m. Eastern time)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Webcast:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Conference call and replay accessible at www.ligand.com</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conference Call:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(877) 407-4019 within the U.S. </font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201) 689-8337 outside the U.S.</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Passcode: Ligand</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Replay:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(877) 660-6853 within the U.S. </font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(201) 612-7415 outside the U.S.</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Passcode: 13586354</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">About Ligand Pharmaceuticals </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand&#8217;s goal is to produce a bottom line that supports a sustainably profitable business.  By diversifying our portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies address the unmet </font></div><br><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s6A726213AB2B5F51C0EF420EF0C87306"></a><div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, diabetes, fungal infections, muscle wasting, dyslipidemia, anemia and osteoporosis. Ligand&#8217;s Captisol platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Lundbeck Inc., Eli Lilly &amp; Co. and Spectrum Pharmaceuticals. Please visit www.captisol.com for more information on Captisol. For more information on Ligand, please visit www.ligand.com.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Follow Ligand on Twitter @Ligand_LGND.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date o</font><font style="font-family:inherit;font-size:10pt;">f this release.  Such statements include those regarding Ligand&#8217;s expected second quarter revenues, growth in profits and cash flow from operations, debt repayment, and Ligand&#8217;s share repurchase program. Words such as &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; and &#8220;will,&#8221; and similar expressions, are intended to identify forward-looking statements. Actual events or results may differ from Ligand's expectati</font><font style="font-family:inherit;font-size:10pt;">ons. For example, Ligand may not receive expected revenue from material sales of Captisol, expected royalties on partnered products and research and development milestone payments.  In addition, there can be no assurance that Ligand will achieve its guidance for 2014 or beyond, that Ligand's 2014 revenues will be at the levels or be broken down as currently anticipated.  The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price.  Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at  www.ligand.com as well as in Ligand's public periodic filings with the Securities and Exchange Commission available at www.sec.gov.  Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.  This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">###</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ligandlogo06.jpg
<TEXT>
begin 644 ligandlogo06.jpg
M_]C_X``02D9)1@`!`0$`W`#<``#_VP!#``(!`0$!`0(!`0$"`@("`@0#`@("
M`@4$!`,$!@4&!@8%!@8&!PD(!@<)!P8&"`L("0H*"@H*!@@+#`L*#`D*"@K_
MVP!#`0("`@("`@4#`P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P``1"`"B`<$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_,CUHR.F
M:_!3QY^V9^U1\2-6GUCQ1\>O%#//,9##:ZQ+;Q1G)P$2-E55&3@`5I?!;]M/
M]J?X:^.=)U'P]\<O$<B)J,7FV6HZK+<V]PA==R21RL0RD<>HZ@@X-.S`_=FB
MBBD`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`'XE_MM?M1_M$ZO^U+\0-"G^,_B.&PT;QKJEAI=C9:M+!#;V\%U+%&B
MI&P`PBC)ZDY)Y->?^"/VM/VE_AYXA@\3^&/CEXGCN;>16`GUF::.0`YVNCL5
M93T((Y%/_;%_Y.Z^*G_91]<_]+YZ\XJTM`/Z+M$N9KW1K2]N"#)-;1NY`XW%
M03_.K1(`R>U4O#/_`"+FG_\`7C%_Z`*ND9!'K4`?FC\3/B9?_M0>'I?VJ?C3
MI-_XD\!ZA\0HO"OP^^',&OOIEE,I9@+V[=`2S%L#.1@ALX55%4='U:X^"S>.
MOC!^RCX$OO`.L_"'4[,^.?!=OXI;5]#URQG9D9E<L?WJ!26YX7!&&&*C\2>`
M[#X,:+%^P/\`M)ZI:>&O#6F_$V+Q)X6\4ZW!+_9VL:3O/FVAEC!*2D$\M@`L
MP8KA<O\`$,&AV6O?$C]D3]A?Q1IGB_2?BW>6;6.G:"\TUIX4A4C[7+-*P,96
M1>`48[50=PH+0'O7_#Z#]F7_`)X7WYI_C17)_P##CKX1?]#??_\`?X__`!-%
M&@'Y;5>\+_\`(S:=_P!?\/\`Z&*HU>\+_P#(S:=_U_P_^ABK>P']%5%%%9@%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1163XYU6XT'P?JNNVHS)9:9
M//&,XRR1LP_45%2:IP<WLM2H0E4FHK=NQY?\8/V]_P!FGX)^(9_"7BSQLUQJ
MEJ2MU8:7:O</"X&=CE1M5NV"<COBL#P=_P`%/_V2O%VIQ:7)XOOM):9PJR:O
MIKQ1@D@#+KN51SU)'OBORSU34[[6M4N=9U.Z>:YNYWFN)G.6D=F+,Q/J22:@
MZU_-=;QCXBEBW.E2IJG?2+3O;S?-OYI)>1_3U#P4X;6#4*U6HZEM9)Q2OUM'
ME>GDVWYG[J6=Y;7]K'>V4Z2PS('BEC;*NI&001U!'.:DKPW_`()Q>)[[Q5^Q
MYX1N]2N'EFM8KFS9W!^Y%<RI&`3UQ&$'X5[E7]$95CHYIEE#&15E4A&=NW,D
M[?*Y_-V:X"65YI7P<G=TIRA?ORR:O\[!1117><`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!^!W[8O_)W7Q4_[*/K
MG_I?/7G%>C_MB_\`)W7Q4_[*/KG_`*7SUYQ5K8#^BOPS_P`BYI__`%XQ?^@"
MKM4O#/\`R+FG_P#7C%_Z`*NU`%#Q%X5\+^,-/.D>+?#=AJEHQRUKJ-FD\9/N
MK@BH/"W@/P-X%@EMO!/@S2='CF?=-'I6G16ZNW3)$:@$UK44`%%%%`'\X]7O
M"_\`R,VG?]?\/_H8JC5[PO\`\C-IW_7_``_^ABM'L!_1511168!1110`4444
M`%&1ZT5^&W[;?Q\^-'C+]IOX@:3X@^)VMRV.G^+M2T^RT]=2E6WAMX;J2-(U
MC#;0-J+GCDC)II7`_<FBOY\_`_QV^-'PWU2WU?P+\5-?TN>VF$D1M-5E5=V0
M>4W;6!P,@@@]P:_H&L)'EL899#EFB4L?4D4-6`FHHJ'4-0L=*L9M3U2]BMK:
MWB:2XN)Y`B1HHRS,QX``!))I`35!J.IZ;I%H]_JVH06L$8R\]Q*J(H]26(`K
M\[OVS_\`@M1<:=J-U\/OV188)/)9H[CQE?VZR(6''^C0L"K#TD<$'LN.3\%?
M$WXY_&+XS:M)K7Q2^)>LZY/(2?\`3[]WC3/4)'G8@]E`%-)@?N?K7[57[,7A
MRX%IX@_:)\#V,I9@([OQ7:1G*G###2#H>M6_#G[1?[/WC!D3PG\</".IF3/E
MBP\1VLI;!P<;7.>>*_GZI58JP93@@Y!%/E`_HV1TD021N&5AE64Y!'K5/Q#I
M4.O:+=Z'<_ZJ\M9()?\`==2I_0U^%/P+_;7_`&F_V=+Z*?X9?%?48;2-\MI%
M_)]ILY!GE3#)E5SZKM;T(/-?IK^PE_P5)^'7[5<\'PZ\>V<'AGQNRXALC-FU
MU,A<L;=FY#<$^4V3CH6YQ$X*47%[,:;B[K<^$_C3^S9\6_@?XRO?"WBKP1J2
MP07+I9ZDEF[07<0;"R(X&T@C!QU&<$`U@^%/A3\3/'.KQ:#X0\`ZOJ-W,X5(
M;73Y&.3T)(&%'N<`=37[:W%O%<Q^5+&K#.<,N13(+*"VR8($3)^;8H&:_$:O
M@M@98MRABY*G?X>1-I=N;F2^?+\F?N=+QQS"&$4)X.,JB5N;G:3??EY;_+F^
M://?V2/A+J?P,_9Y\,_##6BGVW3K-VO1&^Y5FEE>:10>X#2$?A7I%5=;US1O
M#6D7&O\`B'5;>QLK2)I;J[NYECCB0#)9F8@`#U-?"'[47_!;[P5X/OKKPC^S
M/X33Q%=19C/B/5&:.R5NYBC'SS#J,DH,\C<.O[-@L)1P&#IX6BO=IQ45Z122
M_!'XIC<76Q^,J8JL[SJ2<GZR;;_%GWS6!XF^*OPP\%R>3XP^(NA:4^0-FHZM
M#"<\\8=AZ'\J_$SXQ?\`!03]KWXX7$A\8_&O5K>U?(&FZ)+]AMU4_P`.V#:6
M'^^6/J37CMS=W5Y*9[RYDE<]7D<L?S-=?*<Q^]B_MC?LDM,+9?VGOA\9"^T1
MCQC9;BV<8QYO7-=1X;^+'PN\8R"'PC\2-!U1RVT)I^KPS'/'&$8\\C\Q7\\]
M/@N+BUD$UK</$XZ/&Y4C\11R@?T:Y'K17X=?`3_@HU^UI^S[?6X\._%"\U?2
MX6_>:)XBD-Y;R)_=!<[X_8HRX^F17ZC_`+#O_!0'X8_MG>')+:QB&B^*]/A#
MZKX=N)PS;<X\Z!N#)%D@$X!4D`CD$IJP'OU%%%(`HK\8_P#@I_\`&[XN:O\`
MMC^-_"%U\1=872=)ODM-/TN'4)$MX8O)C)`C5MN23DG')Z]*\L_9W^.GQA^'
MGQ;\-7OA#XDZU9@:[:B2WCU*7R95:9`R/'NVNK`8((YJN4#][Z*P?B3\3?`?
MP@\&WGC_`.)7BBTTC2+"/?<WEW)M4>B@=68]`H!)/`!K\R_VMO\`@M+\4?'U
M[=^$?V9[=O"^AY,8URXB5M0N5[E0<K`#VQE_<$X"M<#]/?%'CKP3X(MOMOC/
MQAI>D0GI+J=_'`IYQU=AWXKD;3]KC]E:_O#IUC^TGX#FN!G,$7BZS9^.O`DS
MQ7X-^)_&'BSQMJLNN^,?$U_JM[/(7FNM1NWFD=CU)9R2:SJ?*!_15H'BCPUX
MKLAJ/A?Q!8ZC;G&)[&[29.>1RA(J]7\\?@7XE_$+X8ZS%XA^'?C75-%O86W1
MW&FWKPM]#M/(]0<@]Z_03]AK_@LM?:KJ]G\,/VN;FW7[0Z0V/C*"!8E5SP!=
M(H"@$X_>J`!U88Y":`_1BBFPS0W,*W%O*KHZAD=&!#`\@@CK3J0!1110`4DD
MD<,;2RN%502S,<`#U-?*/[=O_!4KX<?LK//\//A_;6WB?QML(DLTN1]ETMN@
M^T,N3O'7RAAO4KD9_,CXZ?MH?M+?M%W\MQ\3OBMJ4]K(^4TFRE^S6<8R<`0Q
MX4XS@%LMZDT[,#]L?$?[2/[//@^1X?%GQU\'Z8T;!76_\2VL)4GH#ND&#2^&
M/VC_`-GOQK,MOX/^.G@_5)'8JB:?XDM9BQ'8!'.3S7\_9)8EF.2>I-*K,C!T
M8@@Y!!Y!I\H']&RLK`,K`@C((/6EK\-_V:O^"A7[3G[,6H0Q>$_'EQJFB*P\
M_P`.ZY(US;.@_A3<=T/'0QD>X/2OU4_8S_;Y^#G[8_A_9X<N?[)\36L`?5/#
M%[,#-'C&Z2(\>=%D_>`R,C<!2:L!^07[8O\`R=U\5/\`LH^N?^E\]><5Z/\`
MMB_\G=?%3_LH^N?^E\]><52V`_HK\,_\BYI__7C%_P"@"KM4O#/_`"+FG_\`
M7C%_Z`*NU`!1110`4444`?SCU>\+_P#(S:=_U_P_^ABJ-7O"_P#R,VG?]?\`
M#_Z&*T>P']%5%%%9@%%%%`!1110`5^!'[6?_`"=3\3/^R@ZS_P"ETU?OO7X$
M?M9_\G4_$S_LH.L_^ETU5'<#SY>H^M?T8Z7_`,@VW_ZX)_Z"*_G.7J/K7]&.
ME_\`(-M_^N"?^@BB0$]?F]_P6B_;5U%-17]DGX<:R\,*1)<>,[BWDP9"WS16
M>1SC&'<=#N0=F%?HQK6JVNA:/=ZW?2!8;.V>>9CV5%+$_D*_GR^+GQ%UCXN_
M%#Q!\4-?=C=Z]J\]],&;.SS'+!![*"%`[``4D@.=KWK]C3_@GI\:?VR;J75?
M#9AT3PS:3B*]\2:C$QC+=TA08,S@<D`A1QE@2*\T^`?PFU3XZ_&CPS\(M'D,
M<NOZQ#:/.%SY,1;,DF.^U`S8[XQ7[V_#;X>>$OA/X%TOX=>!M'BL-*TBS2VL
M[:%0`%48R?[S$\ECR222233;`^-O#G_!"+]GFQTQ(/$WQ6\5:A=_\M+BW6WM
MT/T38Y`^K&N<^*__``09\'3Z3-=_!7XTZC;7ZC,%EXBM$FAE./NF2(*T?/.[
M:_TK]"**FX'\_7QW^`/Q4_9N\?S_``V^+GAF33M1A421,#NAN8B2!+$XX=#@
MC(Z$$'!!%<GIFIZCHNI6^L:/?S6MW:S++;7-O(4DBD4Y5E8<@@@$$5^S_P#P
M5*_9JT+X_?LLZWK2:8K>(/"-I)JVBW:(-X6,;IHB>I5XPW&<;@I[5^+-6G<#
M]L?^":O[7<G[6GP`AU+Q+=(WBGPZZ6'B)1@&9MN8[G`Z"102>V]7`X`KZ'K\
MAO\`@BG\4[GP3^UW_P`(')=;;/Q=HEQ;21M)A3/"IGC/N<)(H_W_`,#^O-2]
M&!\6_P#!<KQAKV@?LL:+X>TB^D@@UGQ=%%J/EN09HD@F<1G'52X5B/5!7Y,U
M^[/[;7[)>B_ME?!9OA7J7B)M'NK?48[_`$O4UMO.$,Z*Z89-R[E99&!`(Z@]
ML5YA^RC_`,$C_P!GO]GB>+Q1XW(\=>(XFW17VK602TM_3R[8LZY']YRQ]-M-
M.R`_-OX`_L`_M5?M(QQ:C\/OA?=0Z5*V%US6C]DM".Y5W&9`._EAJ^I/`G_!
M`[Q9>6L5Q\2OVA;&PE.#-:Z-H;W('JHDDEC_`#VGZ5^ED4,4$:PP1*B*,*J+
M@`>@%.I78'Y[:G_P0(\'26;+HW[2FIQ7&1L>Y\-QR)]"%G4_CG\#7SS^TM_P
M2+_::^`&B77C/05L_&6AVB%[FXT-'%U!&!DN]NPW;0,Y*%L`$G`K]CZ"`PPP
MR/0T)M`?SCD%2588(/(-=)\(?BMXS^"'Q(TGXI>`-2:UU31[M9[=P3M<#[T;
M@$;D9<J1W!-?1W_!7_\`9FT'X"?M'P^+/!FGK:Z-XVM9+]+6)<1P7:,%N%4=
M@2R28[&0]L5\FU6Z`_H0^"GQ7\._'/X4:!\7/"F18:_IL=U"C-EHR1AHS[JP
M93[J:ZBOC7_@A_X_N?%/[)-_X1O9&+^&_%5Q;P`MD""6.*9<>GSO+Q[>_'V5
M4/0#\.O^"E?_`"?3\2/^PXO_`*(BKR#P1J]IX?\`&FD:]?[O(LM4MYY]BY;8
MDBLV!W.`:]?_`."E?_)]/Q(_[#B_^B(J\,K1;`>[_MT_MT>/OVR_B";RZ:;3
M?"FFRL/#^@"7(0=//EQP\K#DG^$':.,D^.>#?!/B_P"(GB2U\(>!?#5[J^J7
MD@2UL-/MVEED/LJC/U/0=ZZ'X`?`#XE?M*?$JR^%WPOT5KJ^NVS-.P(AM(00
M&FE;'R(N1SW)`&20#^SW['G[$GPD_8\\$IH_A#3X[[7;F)?[:\27,(\^[?`R
M%Z^7$#TC!QW.3DU+=@/SX^&7_!$+]JCQCI2:KXV\0^'?"QE3<EG>7+W,Z_[P
MA4JO_?1/J!3/BC_P1'_:K\$Z1)K'@K6_#WBOR4W/96-R]O<-Z[%F4*W?C<"<
M<`GBOUOZ=**7,P/YU?$OAGQ%X-UZZ\+^+=#N]-U*QF:&\L;ZW:*6%P<%65@"
M#5&OUC_X+&?L>Z%\3_@W<?M$^$M'2/Q-X2B$FHR6\0#7VGY&\/CJ8OO@]E#C
MTQ^3E4G<#]5O^"+_`.UWJ?Q6^'-[^SQX[U1[G6/"4"S:/<W$NZ2?3F;;L)/+
M&)R%S_==!VK[BK\//^":_P`4;KX4?MI^!M6CN3';ZIJJZ1?_`#[0T5U^Z^8G
MC`=D;G^Y7[AU+5@"OF?_`(*;?MKK^R7\'!I?@^\C_P"$S\3*\&AJ<$VD8P)+
MHJ0<[0<*#P6(ZA2*^EV944LQ``&237X;_P#!0_\`:$NOVC_VJO$GBR&_\[2=
M,N6TK0`K?(+2!V4./]]M\G_`_:A*[`\6U#4+[5K^?5-4O);BYN9FEN+B>0N\
MKL<LS,>22222>M)965YJ5Y%IVG6DMQ<3R".""",N\CDX"JHY))Z`5%7ZC?\`
M!(+]@S0_!G@BR_:E^*>A+/K^LQ^;X7M;N'C3K0Y`GP>/,E'*MCY4(QRQJF[`
M?.'P5_X(S?M9?%/18/$GBH:3X.M;F/?#!KDKF[QC@M#&I,?T<JP]*[7Q?_P0
M=^.VF6+W/@OXP>&M5F5`5MKN":U+'!)`;#CK@#/KSBOU,HJ>9@?S_P#QQ_9O
M^-G[./B'_A&OC'\/K_1YG)^S7$L>ZWN0,\Q3+E'Z=CGU`KGO`GCWQC\,?%EE
MXZ\`>([K2M6TZ82V=]9RE'C;TXZ@C(*G@@D$$&OW\^+/P@^''QR\$W?P]^*7
MA2UU?2KQ")(+E,F-L8#QMUC<=F4@BOQU_;__`&!/&?[&_C<ZAIJW&I^"=4G/
M]BZR8\F$]?LTY'"R`=&X#@9'(8!IW`\-\?\`C76OB3X\UOXB^)&B.HZ_J]SJ
M5^84VH9YY6E?:.PW,<#M61115`?T5^&?^1<T_P#Z\8O_`$`5=JEX9_Y%S3_^
MO&+_`-`%7:S`****`"BBB@#^<>KWA?\`Y&;3O^O^'_T,51J]X7_Y&;3O^O\`
MA_\`0Q6CV`_HJHHHK,`HHHH`****`"OP(_:S_P"3J?B9_P!E!UG_`-+IJ_?>
MOP(_:S_Y.I^)G_90=9_]+IJJ.X'GR]1]:_HQTO\`Y!MO_P!<$_\`017\YR]1
M]:_HQTO_`)!MO_UP3_T$42`XG]J:_NM,_9I\?WUE!YLJ>#M2V)@\YMI!V^N:
M_`3KS7]#_P`1?#">-OA_KO@R1RJZOH]U9,P["6)DS_X]7\].LZ3?Z#J]UH>J
MVYBNK*Y>"YB;JDB,58?@0:(@?37_``1TTNQU']NWP[/>C+6>E:C/;J<8,GV5
MT[]<!V/U`/:OV5K\(/V&?C-8?`']J[P7\3M9D"6%IJOV?4I3_P`LK>X1H)'_
M`.`K(6_"OW<MKF"\MX[NUF62*5`\<B-D,I&00>X(I/<!]%%%(#,\:V^F7?@W
M5K76V"V4FF3K=DG`$1C8/_X[FOYVLYYK]Q_^"B_QUT[X"?LD^*_$$EZL>H:M
M8/I.C1;L-)<7"F/*_P"ZA=_HG:OPXJH@>Z?\$TI[^W_;F^'3:<K%FUIEDVQ[
MOW9AD#]N!M)Y[5^XE?C?_P`$<?A_>>,_VVM(UV.$FU\-:7>:A=-@X!,1@C&0
M>#OE4^X4BOV0I/<`HHHI`%%9OB;QEX1\%Z<VK^,/%.FZ3:(,O<ZE?1P1J/4L
MY`KQ?QM_P4Y_8:\!3-;:M\?-.NI5_@T>UGO<G!.,P1LO;UQR*`/>J*^2-1_X
M+6_L364PBM;WQ3>*5R9+?0,*#Z?O)%.?PJO_`,/N?V+_`/GV\8_^"./_`./4
M`</_`,%Z_#UO/\'_``+XIPHEM?$<]MDCDK)!NX/IF(?I7Y?5]P?\%0/^"@_P
M#_:[^$F@>"OA/#KJWNF^(?MMP=5TY(4\OR)$X*R-DY8<8KX?JX[`?I;_`,$"
MM3C/A'XCZ-M;>NI:?-GM@QS+^?%?H77YS_\`!`C_`(]/B3_UTT[^4]?HQ4O<
M#\.O^"E?_)]/Q(_[#B_^B(J\,KW/_@I7_P`GT_$C_L.+_P"B(J\,JUL!^VW_
M``3;_9A\`?L\?LV:!JOAVV6XUGQ7I%KJVMZO)$!+,TT2R)$.ZQQA]H7/7+=6
MKZ"KA_V8O^3:_AY_V(VD_P#I'%7<5F`4444`9OC'PW8^,O".J^$-4B62VU73
M9[.Y1QPT<L;(P/MAC7\\_B?1)O#/B74?#ERC+)I]]+;2*ZX(9'*D$=CD5_15
M7\_W[3.F1Z+^TA\0-'BE9TM/&^JPJ[=6"WDJ@G\JJ(&+\+M7N?#_`,2_#VNV
M982V>N6D\>URIW+,C#D<CIUK^AF)_,B60C&Y0<5_.7#--;RK<6\K)(C!D=&P
M5(.001T-?T8:<2=/@).285R3]!2>X'`?M;_$N?X/?LS>./B/9SF.YTSPY<M9
MR+U6=DV1$>^]EK\#"2QRQR3U-?LI_P`%C/$4VA_L+:_90D@:KJVGVDA!`^7[
M0LO\XA7XUTX@=S^S/\)I_CI\?O"/PGB1C'K>N007;*,E+?<&F;\(PY[=*_??
M2=*T[0M*MM$TBT2WM+.W2"U@C7"QQHH55`[```?A7Y`?\$7O",/B3]MNQU>X
M@WKH?AZ_O4)0D!V18![`XF)&?3UK]AZ);@%%%%2`5@?%'X8^"OC)X"U/X;?$
M+0XM0TG5K5H;JWE7UZ.I_A=3AE8<@@$=*WZ*`/Y\/CCX"L_A7\:O&'PPTZ^D
MN;?PWXIU#2X+F90'E2WN9(E=@.`2$!/UKEJ]'_;%_P"3NOBI_P!E'US_`-+Y
MZ\XJUL!_17X9_P"1<T__`*\8O_0!5VJ7AG_D7-/_`.O&+_T`5=J`"BBB@`HH
MHH`_G'J]X7_Y&;3O^O\`A_\`0Q5&KWA?_D9M._Z_X?\`T,5H]@/Z*J***S`*
M***`"BBB@`K\"/VL_P#DZGXF?]E!UG_TNFK]]Z_`C]K/_DZGXF?]E!UG_P!+
MIJJ.X'GR]1]:_HQTO_D&V_\`UP3_`-!%?SG+U'UK^C'2_P#D&V__`%P3_P!!
M%$@)Z_)#_@L9^R5<_!OXWM\<_#%FH\.^-[AI;C9M'V;4^6F3`[./W@/<EQVK
M]9M8U?3=`TFZUW6;V.VM+*W>>ZN)FVI%&BEF8GL``3^%?A[^WG^U]XC_`&OO
MC=>>*7O)D\-Z9(]KX7TYB0L5L&/[TJ0,22<,Q/(X7HHI1W`\2K[?_8._X*\:
MO\"/#5E\(/V@-*O]>\/68$6F:U:R[[S3X1P(F5C^^C4<+\P91P,@`#Y"^&7P
ME^)/QF\1/X3^%G@R^US48[26Z>TL(MSK%&NYV/X<`=22`,D@'%U;2-6T'4IM
M'US3+BSN[>0I<6MU"T<D;#@JRL`0?8U3LP/VW\+?\%-_V&?%FG+J5I^T%I5H
M"H+0:K#-:R*3G@K(@R00>F1T.<$$\U\6?^"NW[%OPUTN>70_'TOBK4$'[G3M
M`LI6$A]YG58P/?<3[&OQEHI<H'L7[9'[:?Q/_;+\?)XF\8G^S](L04T3P[;7
M#/!9J>K$G'F2MQN<@$@```#%>.U?\,>%?$WC76X/#7@_P]>ZIJ%TX2WLM/M6
MFED;T"J"37Z)?L`_\$?M2T76;#XR?M8Z;"'M76?3/!;%906QE7NR"5."<B(=
MU^8]5IW2`]4_X([?LG:E\"O@C<_%;QMI36VO^-Q%-'!,F)+;3U!,*D'E6<LS
MD=<;,\BOL.DCC2*-8HT"JH`55&`!Z4M0!!J>IZ=HNG3ZOJU]#;6MM$TMQ<3R
M!$B11EF9CP`!R2:_.7]L[_@M1J2:G=?#[]D>&$6\1,<_C*^@+&4]#]FA<`*!
MVD<'/91P3=_X+:?M>ZKI/V/]DWP-J9A%U;I?>+I86(9HVYAM3_LL/WC#N-@Z
M$Y_-NJ2`W_B#\4_B3\5]:?Q%\2_'>K:]>R-DW&JW[S,/9=Q(4=L#``XK`KWO
M]B#]@#XH_MHZ_-=:3<KHWA73IQ'JWB*XBW@28#>3"F1YDF"">0%#`D\@']*O
M@Y_P2>_8P^$UG";[X;CQ5?(`9+[Q3)]I#L/^F.!$![;3[YIW2`_%K!]*,'T-
M?T%:%^S_`/`CPO&(O#?P6\)Z>JQA`MEX=MH@%_N_*@X]JT?^%6_#+_HG6@_^
M"B'_`.)I<P'\\A&.M%?J!_P7)\'>$?#G[/OA.Z\/>%=-L)7\7;7DLK&.)F7[
M-*<$J!D9`XK\OZ:=P/T@_P""!'_'I\2?^NFG?RGK]&*_.?\`X($?\>GQ)_ZZ
M:=_*>OT8J7N!^'7_``4K_P"3Z?B1_P!AQ?\`T1%7AE>Y_P#!2O\`Y/I^)'_8
M<7_T1%7AE6M@/Z`/V8O^3:_AY_V(VD_^D<5=Q7#_`+,7_)M?P\_[$;2?_2.*
MNXK,`HHHH`*_`C]K/_DZCXE_]E`UG_TNFK]]Z_`C]K/_`).H^)?_`&4#6?\`
MTNFJH[@>?5_1EIO_`"#K?_K@G\A7\YM?T9:;_P`@ZW_ZX)_(4GN!\=_\%Q"1
M^R#IX!//C&TSS_TRGK\D:_7_`/X+6Z)_:G[%DNHK'(QT[Q-8S?)T4,7C);V^
M<?B17Y`54=@/MG_@A7_R='X@_P"Q-E_]*(:_5^OR#_X(G>)!HO[:`T>2<@:O
MX6OH$CW`!W0QS#KR<+&_2OU\J7N`4444@"BBB@#\#OVQ?^3NOBI_V4?7/_2^
M>O.*]'_;%_Y.Z^*G_91]<_\`2^>O.*M;`?T5^&?^1<T__KQB_P#0!5VJ7AG_
M`)%S3_\`KQB_]`%7:@`HHHH`****`/YQZO>%_P#D9M._Z_X?_0Q5&KWA?_D9
MM._Z_P"'_P!#%:/8#^BJBBBLP"BBB@`HHHH`*_`C]K/_`).I^)G_`&4'6?\`
MTNFK]]Z_`C]K/_DZGXF?]E!UG_TNFJH[@>?+U'UK^C'2_P#D&V__`%P3_P!!
M%?SG+U'UK^C'2_\`D&V__7!/_011(#YU_P""LOQ#U+X>_L.^*GT>=XKC69+7
M2Q-&<%4FF7S!_P`"C5U_X%7XL5^RG_!8;P!JGCC]B76;W2+1II-`U.TU.55)
MR(4<I(V.^%D+'T"D]J_&NG'8#]2/^"$'PV\/:?\`!7Q9\6%MX7U74_$/]FM,
M>9([>"&.0(/[H9IB3CKM&?NBOK/XN?LN_L]_'="?BU\(M#UJ;&%O;FR47*CT
M$RXD`]@U?D5^P1_P4!\9?L4^([VS;1/[<\*ZS(CZKI'G;)(Y%X$\+'A7V\$$
M88`#C`(_0'P7_P`%GOV)O$UI#+KWB'7-`FDV"2'4M#DD\LD\Y:#S`0.IQZ\9
MI-.X$FN?\$9/V'=7N1<6OA?7].Y8M'8^()-ISCM('QCMC'6K_A;_`((_?L+>
M&9(YI_AQJ&JO'U.J:[.X?YL\JC*OMP!Q6S:?\%5_V`[VX2UA_:$ME=S@&;0=
M1C4?5GMPH_$UL6'_``4?_8<U*Y%K;?M)>'E8@G-P\D2\?[3H!^M+4#T+X8_`
MOX-_!>R:P^%'PQT/P_&Z@2'2]-CB>3_?<#<_U8FNKKRO2OVX?V0-<G-MI?[2
M/@^5QC(_MN)>IQ_$17H7ASQCX1\8V0U+PCXIT[5;<G`GTV^CG0_\"0D4@-*B
MB@].*`/P?_;J\;7GQ!_;"^(OB6]E9W_X2FYM%+#HENWV=%^@6(#\*\GKTC]L
M/0+OPS^U9\1M'OL^8GC349#E<<27#R#C)[,*\WJUL!^]?[&WPBT?X'?LR^#O
MA[I-@D#0:)!/?E4`:6ZE022NQ'4EV(SZ`#H!7IM>;?L@_%;2/C5^S1X,^(6D
M7HF^UZ#;QW?(W)<Q((YD;'0AT;^8X->DU`!115/Q!X@T3PIH=WXE\2:K!8Z?
M86[SWEY<R!(X8D4LSLQX``!-`'Q+_P`%XO\`DW;PC_V./_MK-7Y6U]8_\%1/
MV^]._:U\7VGP^^&@;_A"_#MVTMI>2Q;9-2N=NTSX8!DC`+!5."02Q&2`/DZK
M6P'Z0?\`!`C_`(]/B3_UTT[^4]?HQ7YS_P#!`C_CT^)/_733OY3U^C%2]P/P
MZ_X*5_\`)]/Q(_[#B_\`HB*O#*]S_P""E?\`R?3\2/\`L.+_`.B(J\,JUL!_
M0!^S%_R;7\//^Q&TG_TCBKN*X?\`9B_Y-K^'G_8C:3_Z1Q5W%9@%%%%`!7X$
M?M9_\G4?$O\`[*!K/_I=-7[[U^!'[6?_`"=1\2_^R@:S_P"ETU5'<#SZOZ,M
M-_Y!UO\`]<$_D*_G-K^C+3?^0=;_`/7!/Y"D]P/%/^"D?@.3XB_L1_$'0K>V
M\V:#1A?P``%@UM*EQQD'!(C(^A(R,YK\.*_HMU_1=/\`$FA7OAW5K<2VM_:2
M6US$PX>-U*LOX@D5_/W\;OA=J_P4^+OB/X4:XCBXT'5YK0L_61%8[']PR;6!
M]&%.('8_L)_%.V^#/[7'@3Q[?W?D6D.NQVU].20(X+@&"1CCL%D)/L#7[NJR
MNH92"",@CO7\Y*LRL&5B"#D$'D5^T/\`P3$_;#TG]I_X"V6@ZYJZ-XP\*VL5
MEKMO(_[R=%&V*[&?O!U`W'LX;U%$@/I:BBBI`*SO%OBSP[X$\,7_`(R\7:M#
M8:9IEJ]S?7D[82*)!EF/X=NII_B;Q/X=\&:!=^*?%FM6VG:;8PM->7MY,(XH
M4'5F8\`5^2'_``4L_P""D=Y^U1J?_"J?A/+=67@33[@M+*Y:.36IE;Y9'7/$
M0P"B$9S\S<X"M*X'SG^T%XVT?XE_'OQO\1_#OF?V?X@\7ZEJ5CYR;7\F>ZDE
M3<.QVN,BN0HHJP/Z*_#/_(N:?_UXQ?\`H`J[5+PS_P`BYI__`%XQ?^@"KM9@
M%%%%`!1110!_./4EG=36-W%?6Y`DAD5T)&<,#D5T/Q>^$GCOX'?$'4?AK\1M
M!GT_4].G9'2:,J)4!(65"?O(V,AAP17-5H!]5_\`#YG]N;_H<-#_`/"=@_PH
M_P"'S/[<W_0X:'_X3L'^%?*E%*R`^J_^'S/[<W_0X:'_`.$[!_A1_P`/F?VY
MO^APT/\`\)V#_"OE2BBR`^J_^'S/[<W_`$.&A_\`A.P?X5]@?\$J?V__`(I_
MM::GXG\`?&8:?-JFCVL5_87]C:K`98&?RW1T!Q\K%"&`'W\'H*_)2OO[_@@G
MX+UF;XH>.OB)]ED&GVV@0Z=YY3Y'FEG67:#W(6+)'^T/:DTK`?IU7X$?M9_\
MG4_$S_LH.L_^ETU?OO7X&_M@Z??Z9^UA\2[74;.6"0^/-6D$<T94E'O)71L'
ML58$'N"#1'<#SE>H^M?T8Z7_`,@VW_ZX)_Z"*_G1MK>>[N8[6UA:261PL<:+
MEF8G```ZDFOZ+M-!73K=2,$0)D'Z"B0#-;T72_$>C77A_7+&*ZLKZW>"[MID
M#)+&ZE64@]002*_';_@HK_P3HU7]D'6#X]\):_;7W@O5;XIIT=S=HE[9NQ)$
M+(2#,H&,.@/'W@O4_JW^T9\??!'[,_PBU;XO^/K@BSTV("&UC/[R[G8XCA3_
M`&F;'T&2>`:_$;]J+]J#XF?M8?%"Y^)7Q'U#KF+2],A8^1I]ODE8HP?S+'EC
MR:(W`\XHKM/@!\!?B%^TG\4=.^$WPTTY9]0OW)>64D16L(Y>:1@#M11R>YX`
M!)`/Z?\`@#_@B=^R3HO@^PTWQ\-<UK68[=?[1U*+5GMTFEQ\Q2-.%3/`!R<=
M233;2`_(RBOU_P!2_P""*'[%5]*LEI;^*;)0N#';ZZ&#'U/F1L?R.*R]3_X(
M9_L@WVS[)XL\=6>W.[[/J]J=_P!=]LWZ8ZT<R`_)2M/PGXU\8^`]6CU[P1XJ
MU'2+V(@QW>FWCP2*1_M(0:_2CX@_\$%/A==6<C_"OXXZ_8W`3]U'K]K!=(6]
MVA6(@=>QKXA_:K_8D^.O[(&M0V?Q/T2*73+R5DT[7]-D,EI<D<[0Q`9'QSM8
M`XZ9HNF!]"?LB?\`!9WXL_#[5K3PC^TN[>*/#[LL;ZVD0&HV8Z;V(PLZCJ01
MO/)W$\']1/!GC+PO\0O"MAXV\%ZW;ZCI6IVRW%C>VS[DEC89!!_F.H/!K^=J
MOO\`_P""'O[3NJ:/X[U/]EOQ'?O)IVK6\FH^'5D8D6]U&,S1KZ"1,OCIF(]V
M.4T!SO\`P6R_9KU/P+\<;?\`:(T?3R=&\7Q1P:A,B_+#J$,83:?3S(D5AZE'
M_'XBK^A#XR_!WP#\>_AQJ7PL^)>C"]TG5(=DR`X>-ARLD;?PNIP0?4=QD5^0
MG[8?_!,7X]?LO:G=:[HNCW'BGP@'+6^NZ9`7DMX^PN8ERT9']X90^H)P!,#/
M_88_X*&?$K]B_5YM(@L?[<\(ZA/YNHZ!-,49),`>=`_(C?``((*L!R,X(_0K
MP+_P61_8A\66$5QK_C'5?#D[KF2VU;1)G,9QG!:W60'TR#7XX44VK@?K[\2_
M^"U'['G@[3YG\%76M^*KQ0P@@L-,>WC=@<#=)<;-JGKG:3CMGBO@#]L/_@HM
M\=?VOISHFO74>A^%XI=UOX;TJ1A%(0?E>=B<S..V<*.RBO`:]T_98_X)Z?M&
M?M67\%WX6\+/I/AYF4S^)M9C:*V"$G/E#&Z=N#P@(SC)7.:5D@/&-%\-Z_XC
M^U?V#H]Q=_8;*2[O3!$6$$"#+RN?X5&1R>Y`ZD52K]>/B)^Q'\+?V1_^">GQ
M,\+_``WTN6_UF\\(3OK6NW$8:YO2@WGI]R-1DA!P`,DDY8_D/33N!^D'_!`C
M_CT^)/\`UTT[^4]?HQ7YW?\`!`K3=030_B/J[V<@M7N["%)RORM(JRLR@]R`
MRD_[P]:_1&I>X'X=?\%*_P#D^GXD?]AQ?_1$5>&5[Q_P4WT^^T_]NGXAB^LY
M8?.U:.6'S4*[XVMXL,,]0?6O!_:K6P']`'[,7_)M?P\_[$;2?_2.*NXKBOV:
M[>XL_P!G3P!9W<#Q2Q>"M*26.12&1A9Q`@@]"#7:UF`4444`%?@1^UG_`,G4
M?$O_`+*!K/\`Z735^^]?@5^US!/;_M5_$N.XA>-O^$^UAMKJ0<&]E(//J"#]
M#51W`\\K^C+3?^0=;_\`7!/Y"OYT]/T^]U6_@TO3;5Y[BYF6*"&)<M(['"J!
MW))`K^BS3U9+"!'&"(5!![<"D]P)J_.S_@M=^QS?:JEM^UIX!TEY6MH$L_&$
M,"9(B4XANL`=L^6Y[`1^A-?HG5?5=+TW7-,N-&UBQBNK2ZA:*YMIXPZ2QL,,
MK*>"""00:2T`_G/KIOA%\8?B-\"?'=E\2/A;XFGTO5;&3,<T+?+(O>.1>CHW
M0J>#7V9^W?\`\$??&/@C5+[XI?LLZ7+K&@RN\]WX61MUWI^221`#_KH@.BY+
MC&/FKX3U'3=0T>^ETO5K":UN8'*3V]Q$4>-AU#*>0?8U=TP/T>^$/_!>?25T
MF*S^._P5NS>HN);_`,*W"&.4XZB&=@5R?^FAK=\:_P#!>KX06NF,?AU\#_$E
M[>E3M&M7-O:Q*>Q)B:4L/;BOR^HI<H'M/[5?[>O[07[75[Y'Q!UZ.QT2*3?:
M^'-(#16B'/#."297''S.3CL!TKR7PQX7\1>-?$%IX4\):+<ZCJ5_.(;*QLXB
M\DSGHJJ.37H7[./['/Q__:GUI-.^%'@>>:R6;9=ZY=@Q6-KZ[Y2,$C^ZNYO:
MOU?_`&(?^"='PE_8[TQ=>7;KWC&XBVWGB*ZA`\D$8:*V7_EDAYR<EF[G&%#N
MD!^2'[2?[.OC#]E_QY:?#3Q]=0/K$FAVNH7T%N<K:O,"WD[NC%0`"1QG.,C!
M/GU?7/\`P6MT^^M?VU9KRXLY(X;GPQ8-;2LA"R!0ZDJ>AP00?>ODB&&:YF2W
MMXF>21@J(@R6).``/7--`?T4^&?^1<T__KQB_P#0!5VJ7AQ63P]8(ZD$640(
M(Y!V"KM9@%%%%`!1110!4U/0-"UK8=9T6TN_+SY?VFV63;GKC<#BJO\`P@?@
M?_H3-)_\%T7_`,36K10!E?\`"!^!_P#H3-)_\%T7_P`31_P@?@?_`*$S2?\`
MP71?_$UJT4`97_"!^!_^A,TG_P`%T7_Q-'_"!^!_^A,TG_P71?\`Q-:M%`&5
M_P`('X'_`.A,TG_P71?_`!-7M.TO3-(M_LFDZ=!:Q;BWE6\*HN3WP`!4]%`!
M7,^-?@O\(?B/>)J'C_X8:!K5Q&H5)]3TF&9P!T&YU)Q[9KIJ*`.0\+?L_?`O
MP/JJZYX/^#WAG3+V,@QW=EHD$<B$="&5<@_2NOHHH`_+W_@NQ\:]2UCXK^&O
M@+87A&GZ+I(U2^B1S\]W.SHH8=#MB0$?]=3^/P37U)_P6-L]4M?VY]>DU&7>
MD^DZ?):<'B+R%&.@_B#>OUKY;JUL!^P'_!'7]G+1_A+^S#:?%.[L4.N>.?\`
M39[DI\Z6:L5@B!Z[<`R>YD]A7UQ7@G_!,[XG^&?B9^Q=X'/A^[B:;0](CTC4
M[=,!H)[<!"&`Z;E"OD]0V:][J`"BBB@`KR?]N7X=^&_B=^R3X_\`#WB>S66&
M#PQ=W]NQ4$Q3VT33QNOH0T8Y]":]8KYC_P""J_[37AGX%?LOZWX-35XO^$D\
M8V3Z;I-@KCS##)A9YB.H18RPST+,H]:`/QCKW?\`X)E7$]O^W5\.S;S,A?5Y
M$?:<94V\N0?8UX17U5_P1S^%-Y\0OVS=+\3FV9K'PGI]QJ5U+CA9"AAB7/J6
MDS]$-6]$!^QU!`/4445`'EWQ,_8I_91^,%S)??$+X#^'KVYE.9;R*S^S3L<D
MY,L)1^I/>O.KG_@D7^P?<7#SK\)+B(.Y811Z]=A5SV&9"<?C7TM10!X_\-_V
M!/V.OA/?)JG@OX`Z%'=Q,&CNKZ)[R1&'=6N&<K^&*]?1%C4(B@`#``&`*6B@
M!&574HZ@@C!!'!KA+_\`9<_9MU.\DU#4/@-X0FGF;=+*_AZW)8^I^2N\HH`H
M>&O"OAGP9I$7A_PCX>LM+L(!^YL]/M4AB3Z*@`%7Z**`.>\;_";X7_$ORC\0
MOAYHNMF#_4MJNF13E!Z`NI('L*R]"_9M_9\\,:I%K?A[X(^%;*\@.8;FVT&W
M5T/J"$R#[BNUHH`****`"BBB@`KE_&GP3^#OQ&OEU/Q]\+?#^LW*+A;C4](A
MFD`QC&YE)QBNHHH`Y#PK\`/@;X&U5-=\&_"#PUI=['_J[NQT6"*1?HRKD?A7
M7T44`%%%%`!@'J*XGXI_LW_`;XVC/Q7^$NA:[)C`N;[3T:91VQ(`''X&NVHH
M`^;-0_X)(_L&WUTUS'\'9;8,!^ZM]=O`H^FZ4G]:Z#P'_P`$UOV(_AW<QW^B
M?`'2;FYB;<L^KR2WIR"2#MG=E!&>P'05[G10!#8:=I^E646FZ78PVUM"@2&W
MMX@B1J.@51P!["IJ**`,7QG\./A]\1K-=/\`'W@C2=:AC),<>J:?'.$SUQO!
MQT[5C^&OV>/@+X-U:/7O"GP9\+Z=>PL&AN[/0X(Y(R#D%6"Y4@]Q7944`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`?GG_P`%R/V9-9U_
M3]#_`&H/"VFR7"Z5:C2?$:PQD^5;[W>"=@/X0\CH6_VD[=/S3K^C#5M)TS7=
M,N-%UJPANK2[A:*YMKB,.DL;##*RG@@C@BOSA_;`_P"")NM+JMUXY_9*U""6
MTE9I9O".J7.QX223MMIFX9?1)"",?>;@528'QU^S)^US\:_V2_%K>*/A-XB$
M<5P5&I:1>)YEI>J.@D3(P?1U*L.F<9%?>?PH_P""\7PGU*QCM_C5\(=<TJ\P
M!)<>'FBN[<GNVV5XW0=3@;R/>OSJ^)_P*^,GP6U)M)^*WPRUK0)@V`=2L'C1
M_='QM<>ZDBN4((.#3LF!^S.C_P#!8/\`85U92TGQ'U&S*J"5O-!N%//884@X
M[U#K_P#P6._89T,-]F\<:OJ+!`P33]`F.[)Q@%PHR.O)''Y5^-E%'*@/T>^-
M_P#P7AMGLYM,_9X^$$ZS.I$>J^*Y5'E^XMX6;)QTS)UZ@]*^!_BW\8OB5\=?
M&US\1/BOXMN=9U>ZP'N;D@!$!)"(J@+&@R<*H`&>E<W##-<S+;V\322.P5$1
M<EB>@`'6O=?@'_P3<_:W_:"N8)M!^&5UHNES<_VWXEC>SM]N`=RAEWR#!XV*
MP]Q1H@/$=&T;5?$6K6V@Z%ITUW>WDZPVMK;H6>61CA54#J237[2?\$U?V-)/
MV0O@@;;Q5%$?%OB-TN_$31D,(-H/E6P;N(PS9(X+,V,C%5_V)_\`@FA\'?V1
M4A\7W;_\)'XS:#;+KMW%M2UR,,EM'DA`<D;CER.X!(KZ3J6[@%%%%(`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@"OJ.E:7K%JUCJ^FV]U`X(>&YA5T8'L0P(-?*'[6W[/_P`!K*\GDL_@EX1A
M;).Z+PW:J<^0#GB/UYHHJH[@?D#=`+<R*H``D.`/K7LO["/A7PQXP^-LFD^+
M?#EAJEJ-%G<6VHV:3Q[@T>&VN",C)Y]Z**H#]A_@)\'?A'X3\,0:MX5^%GAS
M3+IF8-<Z?H=O#(1_O(@/<_G7I(`'08HHK,`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
..****`"BBB@`HHHH`_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
